Floatz logo

Tegafur Gimeracil Oteracil Potassium

Breast Cancer

Chinese Academy of Medical SciencesPhase 2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
59/ 100

Competitive context

891 Active assets in the Breast Cancer cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB

View all 50 →

Same molecule, other indications

Tegafur Gimeracil Oteracil Potassium is also rated in:

colorectal cancerDormant
B
Indicative ·
57 / 100
View asset →
malignant pancreatic neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
cancerDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →